Ocugen OCGN is building its ocular portfolio around a modifier gene therapy idea: instead of designing a therapy for a single genetic defect, the platform is intended to work across many underlying ...

Explore the latest developments showcased at World ADC, highlighting smarter payloads and precise targeting in drug discovery.

A multinational research team led by researchers at Institute of Science Tokyo, RIKEN, and the University of Toronto has ...

The Mystra platform, developed over 10 years, offers biopharma partners proven analytical power to turn months of R&D into minutes, dramatically increasing the availability of quality genetic insights ...

Cells face constant threats from inside and out. Thus, they’ve evolved sophisticated stress response pathways such as the unfolded protein response (UPR), ...

Funding and clinical trial-based barriers must be addressed to ensure success on the path to developing a DMT for Parkinson’s.

Smart multi-target drugs are reshaping modern therapeutics by addressing the complex, interconnected pathways that drive diseases like Alzheimer’s, cancer, and major depressive disorder. Advances in ...

London biotech startup Ternary Therapeutics has raised £3.6m to scale its AI-powered platform designed to engineer molecular ...

Developing high-quality, safe, and effective drugs is a complex process that requires varied scientific skills and stringent regulatory assessments. Drug development is a process that spans many years ...